Cartilage Degeneration Market Report 2026

The cartilage degeneration market size has grown strongly in recent years. It will grow from $13.4 billion in 2025 to $14.08 billion in 2026 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to increasing incidence of osteoarthritis, expansion of orthopedic surgical procedures, rising aging population, availability of advanced surgical techniques, adoption of joint preservation therapies.

The cartilage degeneration market size is expected to see strong growth in the next few years. It will grow to $17.72 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing investments in regenerative medicine research, rising demand for biologic cartilage repair solutions, expansion of stem cell-based therapies, growing focus on personalized orthopedic care, increasing adoption of advanced cartilage restoration procedures. Major trends in the forecast period include increasing adoption of cell-based cartilage repair techniques, growing use of minimally invasive surgical procedures, rising demand for regenerative medicine solutions, expansion of advanced imaging and diagnostic tools, enhanced focus on long-term joint preservation.

The rising prevalence of obesity is expected to drive the growth of the cartilage degeneration market in the coming years. Obesity is a medical condition characterized by excessive body fat accumulation that can negatively impact health. It contributes to cartilage degeneration by increasing compressive forces on cartilage and elevating inflammatory cytokines. Obesity also causes pathological changes in the knee joint, including abnormal joint loading, malalignment, and muscle weakness. For example, in November 2024, NHS Digital, a UK government health data agency, reported that the prevalence of obesity among children aged 4 to 5 years increased from 9.2% in 2022/23 to 9.6% in 2023/24. Thus, the growing incidence of obesity is fueling the cartilage degeneration market.

Leading companies in the cartilage degeneration market are focusing on regenerative therapies to gain a competitive edge. Regenerative therapies employ advanced biological techniques to restore or replace damaged cartilage, supporting natural healing processes. For instance, in 2023, Zimmer Biomet, a US-based medical device company, launched its Tissue Regeneration System, which uses proprietary scaffold technology to enhance cartilage repair. This system incorporates biocompatible materials that promote cell growth and integration into surrounding tissues, significantly improving healing outcomes. It also offers customizable options tailored to individual patients, increasing treatment effectiveness. These innovations represent a shift toward personalized medicine in cartilage degeneration treatment, addressing the rise of osteoarthritis and sports-related injuries while enabling faster recovery and improved patient satisfaction.

In January 2024, Smith & Nephew plc, a UK-based medical device manufacturer specializing in orthopedics, sports medicine, and advanced wound management, acquired CartiHeal Ltd. for an undisclosed sum. This acquisition allows Smith & Nephew to incorporate CartiHeal’s Agili-C implant technology for cartilage and osteochondral defect repair, expanding its sports-medicine and joint-preservation portfolio and enhancing its capacity to provide regenerative, off-the-shelf solutions for knee-joint lesions. CartiHeal Ltd., based in Israel, develops cell-free, aragonite-based scaffold implants designed to stimulate natural cartilage and bone regeneration, effectively treating cartilage damage without the need for donor tissue, cells, or growth factors.

Major companies operating in the cartilage degeneration market are Johnson & Johnson Services Inc., MEDIPOST Co. Ltd., Medtronic plc, Stryker Corporation, Zimmer Biomet Holdings Inc., Smith and Nephew plc, Osiris Therapeutics Inc., Arthrex Inc., Conmed Corporation, Orthocell Ltd., Bioventus LLC, Aesculap Inc., Vericel Corporation, Anika Therapeutics Inc., Geistlich Pharma AG, MatTek Corporation, Breg Inc., Isto Biologics Inc., OrthoTrophix LLC, CellGenix GmbH, CartiHeal Inc., Cayenne Medical Inc., Collagen Solutions plc, Regentis Biomaterials Ltd., Histogen Inc., BioTime Inc., CollPlant Holdings Ltd.

North America was the largest region in the cartilage degeneration market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cartilage degeneration market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cartilage degeneration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cartilage degeneration market by increasing costs of imported surgical instruments, implants, biologic materials, imaging equipment, and regenerative therapy components. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported orthopedic technologies, while Asia-Pacific faces higher costs for advanced implant manufacturing. These tariffs are increasing procedure costs and limiting access to advanced treatments. However, they are also encouraging domestic production of implants, local development of biologic therapies, and regional innovation in cost-effective cartilage repair solutions.

The cartilage degeneration market research report is one of a series of new reports that provides cartilage degeneration market statistics, including cartilage degeneration industry global market size, regional shares, competitors with a cartilage degeneration market share, detailed cartilage degeneration market segments, market trends and opportunities, and any further data you may need to thrive in the cartilage degeneration industry. This cartilage degeneration market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cartilage degeneration refers to the gradual breakdown or deterioration of cartilage, the smooth, flexible connective tissue that covers the ends of bones in joints. Cartilage acts as a cushion, enabling smooth joint movement by reducing friction between bones. Its degeneration results in pain, stiffness, and reduced joint function.

The primary procedures for treating cartilage degeneration include joint replacements, chondroplasty, osteochondral transplants, microfracture, meniscus transplants, cell-based cartilage resurfacing, autologous chondrocyte implantation, and others. Joint replacement is a surgical procedure in which a damaged or diseased joint is substituted with an artificial joint, called a prosthesis. These procedures are applied to various joints, such as the knee and hip, and are utilized by hospitals, specialty clinics, ambulatory surgical centers, and academic and research institutes.

The cartilage degeneration market consists of revenues earned by entities by provide services such as diagnosis and evaluation, non-surgical management, patient education, physical therapy, and nutritional and lifestyle guidance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cartilage degeneration market also includes sales of over-the-counter medications, joint supplements, topical pain relievers, and hyaluronic acid injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.